Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
|Articles|November 2, 2018
- Pharmaceutical Technology-11-02-2018
- Volume 42
- Issue 11
Pharmaceutical Technology North America, November 2018 (PDF)
Click the title above to open the Pharmaceutical Technology November 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 8 years ago
Guidelines on Integral Drug-Device Combinationsalmost 8 years ago
Detachable AODD Pumpalmost 8 years ago
Advanced Paddle Blender for Labsalmost 8 years ago
Custom Multi-Shaft Mixeralmost 8 years ago
Bioimaging Molecular Probesalmost 8 years ago
User Requirements Specifications–How Difficult Can It Be?almost 8 years ago
Single-Use Bioprocessing Equipment Trends and Adoption by CMOsalmost 8 years ago
Innovations in Prefilled Syringes for Biologic DrugsAdvertisement
Related to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
5